Avidity Biosciences Inc. (NASDAQ:RNA) experienced a notable surge on Friday, gaining 9.02 percent to close at $44.74 per share. This improvement comes after BofA...
Skyhawk Therapeutics has received a significant financial boost in its mission to advance RNA-targeted therapies, securing an additional $2 billion from Merck KGaA. This...